1Michael CW, McConnel J, Peeott J, et al. Comparison of ThinPrep and TriPath PREP liquid-based preparations in nongyneeologic specimens: a pilot study. Diagn Cytopathol, 2001, 25(3):177-184
2Bekkers RL, Melchers WJ, Bakkers JM, et al. The role of genotypespecific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia. Int J Cancer, 2002, 102(2):148-151.
3Soh LT, Heng D, Lee IW, et al. The relevance of oncogenes as prognostic markers in cervical cancer. Int J Gynecol Cancer, 2002, 12(5):465-474.
4Duggan MA. A review of the natural history of cervical intraepithelial neoplasia. Gan To Kagaku Ryoho, 2002, 29 [Suppl 1]:176-193.
5Kruse A J, Baak JP, de Bruin PC, et al. Relationship between the presence of oncogenic HPV DNA assessed by polymerase chain reaction and Ki-67 immunoquantitative features in cervical intraepithelial neoplasia. J Pathol, 2001, 195(5):557-562.
7Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
8George L.Wied,M.D.F.I.A.C:A History of Clinical Cytology and Out-look for Its Future[M].Compendium on Diagnostic Cytology1997:1-5.
9Slagel DD,Zaleski S,Cohen MB.Efficacy of automated cervical cytology screening.Diagn Cytopathol,1995,13:26-30.
10Gillison ML,Chaturvedi AK,Lowy DR.HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women[J].Cancer,2008,113(10 Suppl):3036-3046.
